News

For the quarter ended April 2024, HealthEquity (HQY) reported revenue of $287.6 million, up 17.7% over the same period last year. EPS came in at $0.80, compared to $0.50 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $278.78 million, representing a surprise of +3.16%. The company delivered an EPS surprise of +21.21%, with the consensus EPS estimate being $0.66.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how HealthEquity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total HSA Assets: $27.28 billion versus the three-analyst average estimate of $25.82 billion.
• Total HSA investments: $11.43 billion versus $10.52 billion estimated by three analysts on average.
• HSAs Accounts: 9.1 million versus the three-analyst average estimate of 8.92 million.
• Total HSA cash: $15.85 billion versus the three-analyst average estimate of $15.30 billion.
• Total Accounts: 16,010 thousand versus 15,825.37 thousand estimated by two analysts on average.
• CDBs Accounts: 6,913 thousand compared to the 6,945.47 thousand average estimate based on two analysts.
• Revenue- Service revenue: $118.21 million versus $113.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
• Revenue- Custodial revenue: $121.64 million versus $117.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +28.8% change.
• Revenue- Interchange revenue: $47.74 million versus the four-analyst average estimate of $47.53 million. The reported number represents a year-over-year change of +6.4%.

View all Key Company Metrics for HealthEquity here>>>

Shares of HealthEquity have returned +4% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HealthEquity, Inc. (HQY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.